Zai Lab (NASDAQ:ZLAB) Trading 10.3% Higher – What’s Next?

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) shares traded up 10.3% on Monday . The company traded as high as $20.32 and last traded at $20.5150. 204,580 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 756,187 shares. The stock had previously closed at $18.60.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Weiss Ratings lowered shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. Cantor Fitzgerald dropped their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Zacks Research lowered shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Finally, Citigroup lowered their target price on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.83.

Get Zai Lab alerts:

Check Out Our Latest Stock Analysis on ZLAB

Zai Lab Stock Up 4.8%

The firm’s fifty day moving average price is $20.22 and its 200 day moving average price is $19.91. The stock has a market cap of $2.32 billion, a PE ratio of -12.64 and a beta of 0.85.

Zai Lab (NASDAQ:ZLAB – Get Free Report) last released its earnings results on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The company had revenue of $99.61 million during the quarter. As a group, analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.22 earnings per share for the current fiscal year.

Insider Activity at Zai Lab

In related news, CEO Ying Du sold 2,653 shares of the company’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85. Following the sale, the chief executive officer owned 1,122,626 shares of the company’s stock, valued at $22,957,701.70. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joshua L. Smiley sold 3,017 shares of the company’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $20.45, for a total transaction of $61,697.65. Following the sale, the insider directly owned 117,602 shares in the company, valued at approximately $2,404,960.90. The trade was a 2.50% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 46,187 shares of company stock valued at $930,647 over the last quarter. 4.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is owned by institutional investors.

Zai Lab Company Profile

(Get Free Report)

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.

Featured Articles

• Five stocks we like better than Zai Lab
• D-Wave Earnings Looked Weak, But Investors May Be Missing This
• Nebius Upside Expands as AI Feedback Loop Intensifies
• Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
• Plug Power Flips The Switch On Profitability

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.